Physician profile
Jonathan J Smith
NPI 1477823342
$7,802.53
in general payments reported to CMS, 2019-2025
43 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,692 · 2022: $1,188 · 2023: $1,496 · 2024: $1,654 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,902 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,902.17 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,071.04 | 2021-2025 | |
| Lilly USA, LLC | $674.05 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $635.10 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $440.29 | 2021-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $383.82 | 2023-2025 | Rexulti |
| Pfizer INC. | $364.14 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $327.93 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $308.03 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $279.65 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Clarus Therapeutics INC. | $265.27 | 2021 | |
| Glaxosmithkline, LLC. | $238.43 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $229.21 | 2024-2025 | Spravato |
| Antares Pharma, INC. | $215.10 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $189.17 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $182.31 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.